APO Research
Talk to an analyst

APO RESEARCH · REPORT

Huntington's Disease Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Huntington's Disease Therapeutics Market Outlook and Growth Opportunities 2026

22 December 2025191 pages

Choose your research edition.

Industry ResearchHuntington's Disease Therapeutics Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Huntington's Disease Therapeutics Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Huntington's Disease Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Huntington's Disease Therapeutics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Huntington's Disease Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Huntington's Disease Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Huntington's Disease Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Huntington's Disease Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Huntington's Disease Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Huntington's Disease Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Huntington's Disease Therapeutics market include Teva Pharmaceutical Industries, Prana Biotechnology, Horizon Pharma, H. Lundbeck and F. Hoffmann-La Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Huntington's Disease Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Huntington's Disease Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Huntington's Disease Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Huntington's Disease Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Huntington's Disease Therapeutics Segment by Company

Teva Pharmaceutical Industries

Prana Biotechnology

Horizon Pharma

H. Lundbeck

F. Hoffmann-La Roche

Huntington's Disease Therapeutics Segment by Type

Antidepressants

Anticonvulsants

Antipsychotics

Antidopaminergics

Huntington's Disease Therapeutics Segment by Application

Clinics

Diagnostic Centers

Hospitals

Huntington's Disease Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Huntington's Disease Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Huntington's Disease Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Huntington's Disease Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Huntington's Disease Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Huntington's Disease Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Huntington's Disease Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Huntington's Disease Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Huntington's Disease Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Huntington's Disease Therapeutics industry.

Chapter 3: Detailed analysis of Huntington's Disease Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Huntington's Disease Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Huntington's Disease Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Huntington's Disease Therapeutics Industry Trends Table 2. Huntington's Disease Therapeutics Industry Drivers Table 3. Huntington's Disease Therapeutics Industry Opportunities and Challenges Table 4. Huntington's Disease Therapeutics Industry Restraints Table 5. Global Huntington's Disease Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Huntington's Disease Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Huntington's Disease Therapeutics Sales Volume by Company (k units) & (2021-2026) Table 8. Global Huntington's Disease Therapeutics Sales Volume Share by Company (2021-2026) Table 9. Global Huntington's Disease Therapeutics Average Price (US$/unit) of Company (2021-2026) Table 10. Global Huntington's Disease Therapeutics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Huntington's Disease Therapeutics Key Company Manufacturing Base & Headquarters Table 12. Global Huntington's Disease Therapeutics Company, Product Type & Application Table 13. Global Huntington's Disease Therapeutics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Huntington's Disease Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Antidepressants Table 18. Significant Companies of Anticonvulsants Table 19. Significant Companies of Antipsychotics Table 20. Significant Companies of Antidopaminergics Table 21. Global Huntington's Disease Therapeutics Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Huntington's Disease Therapeutics Sales Volume by Type (2021-2026) & (k units) Table 23. Global Huntington's Disease Therapeutics Sales Volume by Type (2027-2032) & (k units) Table 24. Global Huntington's Disease Therapeutics Sales Volume Share by Type (2021-2026) Table 25. Global Huntington's Disease Therapeutics Sales Volume Share by Type (2027-2032) Table 26. Global Huntington's Disease Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Huntington's Disease Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Huntington's Disease Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Huntington's Disease Therapeutics Sales Value Share by Type (2021-2026) Table 30. Global Huntington's Disease Therapeutics Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Clinics Table 32. Significant Companies of Diagnostic Centers Table 33. Significant Companies of Hospitals Table 34. Global Huntington's Disease Therapeutics Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Huntington's Disease Therapeutics Sales Volume by Application (2021-2026) & (k units) Table 36. Global Huntington's Disease Therapeutics Sales Volume by Application (2027-2032) & (k units) Table 37. Global Huntington's Disease Therapeutics Sales Volume Share by Application (2021-2026) Table 38. Global Huntington's Disease Therapeutics Sales Volume Share by Application (2027-2032) Table 39. Global Huntington's Disease Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Huntington's Disease Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Huntington's Disease Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Huntington's Disease Therapeutics Sales Value Share by Application (2021-2026) Table 43. Global Huntington's Disease Therapeutics Sales Value Share by Application (2027-2032) Table 44. Global Huntington's Disease Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Huntington's Disease Therapeutics Sales by Region (2021-2026) & (k units) Table 46. Global Huntington's Disease Therapeutics Sales Market Share by Region (2021-2026) Table 47. Global Huntington's Disease Therapeutics Sales by Region (2027-2032) & (k units) Table 48. Global Huntington's Disease Therapeutics Sales Market Share by Region (2027-2032) Table 49. Global Huntington's Disease Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Huntington's Disease Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Huntington's Disease Therapeutics Sales Value Share by Region (2021-2026) Table 52. Global Huntington's Disease Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Huntington's Disease Therapeutics Sales Value Share by Region (2027-2032) Table 54. Global Huntington's Disease Therapeutics Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Huntington's Disease Therapeutics Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Huntington's Disease Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Huntington's Disease Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Huntington's Disease Therapeutics Sales by Country (2021-2026) & (k units) Table 59. Global Huntington's Disease Therapeutics Sales Market Share by Country (2021-2026) Table 60. Global Huntington's Disease Therapeutics Sales by Country (2027-2032) & (k units) Table 61. Global Huntington's Disease Therapeutics Sales Market Share by Country (2027-2032) Table 62. Global Huntington's Disease Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Huntington's Disease Therapeutics Sales Value Market Share by Country (2021-2026) Table 64. Global Huntington's Disease Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Huntington's Disease Therapeutics Sales Value Market Share by Country (2027-2032) Table 66. Teva Pharmaceutical Industries Company Information Table 67. Teva Pharmaceutical Industries Business Overview Table 68. Teva Pharmaceutical Industries Huntington's Disease Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Teva Pharmaceutical Industries Huntington's Disease Therapeutics Product Portfolio Table 70. Teva Pharmaceutical Industries Recent Development Table 71. Prana Biotechnology Company Information Table 72. Prana Biotechnology Business Overview Table 73. Prana Biotechnology Huntington's Disease Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Prana Biotechnology Huntington's Disease Therapeutics Product Portfolio Table 75. Prana Biotechnology Recent Development Table 76. Horizon Pharma Company Information Table 77. Horizon Pharma Business Overview Table 78. Horizon Pharma Huntington's Disease Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Horizon Pharma Huntington's Disease Therapeutics Product Portfolio Table 80. Horizon Pharma Recent Development Table 81. H. Lundbeck Company Information Table 82. H. Lundbeck Business Overview Table 83. H. Lundbeck Huntington's Disease Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. H. Lundbeck Huntington's Disease Therapeutics Product Portfolio Table 85. H. Lundbeck Recent Development Table 86. F. Hoffmann-La Roche Company Information Table 87. F. Hoffmann-La Roche Business Overview Table 88. F. Hoffmann-La Roche Huntington's Disease Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. F. Hoffmann-La Roche Huntington's Disease Therapeutics Product Portfolio Table 90. F. Hoffmann-La Roche Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. Huntington's Disease Therapeutics Distributors List Table 94. Huntington's Disease Therapeutics Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Huntington's Disease Therapeutics Product Image Figure 2. Global Huntington's Disease Therapeutics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Huntington's Disease Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Huntington's Disease Therapeutics Sales (2021-2032) & (k units) Figure 5. Global Huntington's Disease Therapeutics Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Huntington's Disease Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Antidepressants Image Figure 10. Anticonvulsants Image Figure 11. Antipsychotics Image Figure 12. Antidopaminergics Image Figure 13. Global Huntington's Disease Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Huntington's Disease Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Huntington's Disease Therapeutics Sales Volume Share by Type (2021-2032) Figure 16. Global Huntington's Disease Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Huntington's Disease Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Huntington's Disease Therapeutics Sales Value Share by Type (2021-2032) Figure 19. Clinics Image Figure 20. Diagnostic Centers Image Figure 21. Hospitals Image Figure 22. Global Huntington's Disease Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Huntington's Disease Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Huntington's Disease Therapeutics Sales Volume Share by Application (2021-2032) Figure 25. Global Huntington's Disease Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Huntington's Disease Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Huntington's Disease Therapeutics Sales Value Share by Application (2021-2032) Figure 28. Global Huntington's Disease Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Huntington's Disease Therapeutics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Huntington's Disease Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Huntington's Disease Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Huntington's Disease Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 33. North America Huntington's Disease Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Huntington's Disease Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Huntington's Disease Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Huntington's Disease Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Huntington's Disease Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Huntington's Disease Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 39. South America Huntington's Disease Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Huntington's Disease Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Huntington's Disease Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Huntington's Disease Therapeutics Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Huntington's Disease Therapeutics Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Antidepressants
  • Anticonvulsants
  • Antipsychotics
  • Antidopaminergics
Applications
  • Clinics
  • Diagnostic Centers
  • Hospitals
Companies covered
  • Teva Pharmaceutical Industries
  • Prana Biotechnology
  • Horizon Pharma
  • H. Lundbeck
  • F. Hoffmann-La Roche

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Huntington's Disease Therapeutics Sales Value (2021-2032)
  4. 1.2.2 Global Huntington's Disease Therapeutics Sales Volume (2021-2032)
  5. 1.2.3 Global Huntington's Disease Therapeutics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Huntington's Disease Therapeutics Market Dynamics
  1. 2.1 Huntington's Disease Therapeutics Industry Trends
  2. 2.2 Huntington's Disease Therapeutics Industry Drivers
  3. 2.3 Huntington's Disease Therapeutics Industry Opportunities and Challenges
  4. 2.4 Huntington's Disease Therapeutics Industry Restraints
3 Huntington's Disease Therapeutics Market by Company
  1. 3.1 Global Huntington's Disease Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Huntington's Disease Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Huntington's Disease Therapeutics Sales Volume by Company (2021-2026)
  4. 3.4 Global Huntington's Disease Therapeutics Average Price by Company (2021-2026)
  5. 3.5 Global Huntington's Disease Therapeutics Company Ranking (2024-2026)
  6. 3.6 Global Huntington's Disease Therapeutics Company Manufacturing Base and Headquarters
  7. 3.7 Global Huntington's Disease Therapeutics Company Product Type and Application
  8. 3.8 Global Huntington's Disease Therapeutics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Huntington's Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Huntington's Disease Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Huntington's Disease Therapeutics Market by Type
  1. 4.1 Huntington's Disease Therapeutics Type Introduction
  2. 4.1.1 Antidepressants
  3. 4.1.2 Anticonvulsants
  4. 4.1.3 Antipsychotics
  5. 4.1.4 Antidopaminergics
  6. 4.2 Global Huntington's Disease Therapeutics Sales Volume by Type
  7. 4.2.1 Global Huntington's Disease Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Huntington's Disease Therapeutics Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Huntington's Disease Therapeutics Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Huntington's Disease Therapeutics Sales Value by Type
  11. 4.3.1 Global Huntington's Disease Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Huntington's Disease Therapeutics Sales Value by Type (2021-2032)
  13. 4.3.3 Global Huntington's Disease Therapeutics Sales Value Share by Type (2021-2032)
5 Huntington's Disease Therapeutics Market by Application
  1. 5.1 Huntington's Disease Therapeutics Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Diagnostic Centers
  4. 5.1.3 Hospitals
  5. 5.2 Global Huntington's Disease Therapeutics Sales Volume by Application
  6. 5.2.1 Global Huntington's Disease Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Huntington's Disease Therapeutics Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Huntington's Disease Therapeutics Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Huntington's Disease Therapeutics Sales Value by Application
  10. 5.3.1 Global Huntington's Disease Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Huntington's Disease Therapeutics Sales Value by Application (2021-2032)
  12. 5.3.3 Global Huntington's Disease Therapeutics Sales Value Share by Application (2021-2032)
6 Huntington's Disease Therapeutics Regional Sales and Value Analysis
  1. 6.1 Global Huntington's Disease Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Huntington's Disease Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Huntington's Disease Therapeutics Sales by Region: 2021-2026
  4. 6.2.2 Global Huntington's Disease Therapeutics Sales by Region (2027-2032)
  5. 6.3 Global Huntington's Disease Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Huntington's Disease Therapeutics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Huntington's Disease Therapeutics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Huntington's Disease Therapeutics Sales Value by Region (2027-2032)
  9. 6.5 Global Huntington's Disease Therapeutics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Huntington's Disease Therapeutics Sales Value (2021-2032)
  12. 6.6.2 North America Huntington's Disease Therapeutics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Huntington's Disease Therapeutics Sales Value (2021-2032)
  15. 6.7.2 Europe Huntington's Disease Therapeutics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Huntington's Disease Therapeutics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Huntington's Disease Therapeutics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Huntington's Disease Therapeutics Sales Value (2021-2032)
  21. 6.9.2 South America Huntington's Disease Therapeutics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Huntington's Disease Therapeutics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Huntington's Disease Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Huntington's Disease Therapeutics Country-level Sales and Value Analysis
  1. 7.1 Global Huntington's Disease Therapeutics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Huntington's Disease Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Huntington's Disease Therapeutics Sales by Country (2021-2032)
  4. 7.3.1 Global Huntington's Disease Therapeutics Sales by Country (2021-2026)
  5. 7.3.2 Global Huntington's Disease Therapeutics Sales by Country (2027-2032)
  6. 7.4 Global Huntington's Disease Therapeutics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Huntington's Disease Therapeutics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Huntington's Disease Therapeutics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Huntington's Disease Therapeutics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Huntington's Disease Therapeutics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Huntington's Disease Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries
  2. 8.1.1 Teva Pharmaceutical Industries Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Huntington's Disease Therapeutics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Huntington's Disease Therapeutics Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Recent Developments
  7. 8.2 Prana Biotechnology
  8. 8.2.1 Prana Biotechnology Company Information
  9. 8.2.2 Prana Biotechnology Business Overview
  10. 8.2.3 Prana Biotechnology Huntington's Disease Therapeutics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Prana Biotechnology Huntington's Disease Therapeutics Product Portfolio
  12. 8.2.5 Prana Biotechnology Recent Developments
  13. 8.3 Horizon Pharma
  14. 8.3.1 Horizon Pharma Company Information
  15. 8.3.2 Horizon Pharma Business Overview
  16. 8.3.3 Horizon Pharma Huntington's Disease Therapeutics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Horizon Pharma Huntington's Disease Therapeutics Product Portfolio
  18. 8.3.5 Horizon Pharma Recent Developments
  19. 8.4 H. Lundbeck
  20. 8.4.1 H. Lundbeck Company Information
  21. 8.4.2 H. Lundbeck Business Overview
  22. 8.4.3 H. Lundbeck Huntington's Disease Therapeutics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 H. Lundbeck Huntington's Disease Therapeutics Product Portfolio
  24. 8.4.5 H. Lundbeck Recent Developments
  25. 8.5 F. Hoffmann-La Roche
  26. 8.5.1 F. Hoffmann-La Roche Company Information
  27. 8.5.2 F. Hoffmann-La Roche Business Overview
  28. 8.5.3 F. Hoffmann-La Roche Huntington's Disease Therapeutics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 F. Hoffmann-La Roche Huntington's Disease Therapeutics Product Portfolio
  30. 8.5.5 F. Hoffmann-La Roche Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Huntington's Disease Therapeutics Value Chain Analysis
  2. 9.1.1 Huntington's Disease Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Huntington's Disease Therapeutics Sales Mode & Process
  6. 9.2 Huntington's Disease Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Huntington's Disease Therapeutics Distributors
  9. 9.2.3 Huntington's Disease Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst